Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Regenovo Biotechnology is a China-based biomedical technology company focused on bio-3D printing, biomaterials, and related tools for regenerative medicine and tissue engineering. Rather than a traditional therapeutics developer, the company appears to commercialize integrated solutions spanning bioprinting equipment, materials, software, scaffolds, medical image processing, and tissue organoid research and production services. Its offerings are used across scientific research, drug development, regenerative medicine, and personalized medical applications. Publicly available sources describe Regenovo as an active private company founded in 2013 in Hangzhou, with products including the Bio-Architect bioprinting workstation line. The company therefore looks best characterized as a life-science tools and biomedical platform company rather than a clinical-stage drug developer.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Regenovo Biotechnology.